Date: 2017-08-08
Type of
information: Submission of a clinical trial application
phase: 1
Announcement: submission of a clinical trial application
Company: Kite Pharma (USA - CA)
Product: KITE-585
Action
mechanism:
- cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy.
- KITE-585 is an anti-BCMA (B-cell maturation antigen) CAR construct designed for high binding affinity to BCMA expressed on the cell surface. KITE-585 contains a receptor derived from a fully human monoclonal antibody and a CD28 costimulatory domain intended for optimized T-cell expansion and function. In preclinical studies, KITE-585 demonstrated activity across a range of low and high BCMA expressing targets and its activity was not impaired by soluble BCMA. In the presence of cell-bound BCMA, KITE-585 induced polyfunctional T cell expansion, and no tonic signaling in its absence. BCMA is expressed on the surface of malignant plasma cells in most patients with multiple myeloma. In addition, it is found on normal plasma cells and certain mature B-cell lineage cells but is absent from other tissues. Because BCMA has been shown to play a potential role in survival and growth of myeloma cells, it is viewed as an attractive CAR T-cell therapeutic target.
Disease: relapsed/refractory multiple myeloma
Therapeutic
area: Cancer - Oncology
Country: USA
Trial
details:
Latest
news:
- • On August 8, 2017, Kite Pharma announced the submission of an Investigational New Drug (IND) application with the FDA to initiate a Phase 1, first-in-human trial of KITE-585, a CAR-T cell therapy engineered to target B-cell maturation antigen (BCMA) in patients with relapsed/refractory multiple myeloma.
Is
general: Yes
